MicroRNAs as Biomarkers for Ionizing Radiation Injury.
biomarker
body fluids
injury assessment
ionizing radiation
microRNA
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
01
2022
accepted:
15
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
Accidental radiation exposures such as industrial accidents and nuclear catastrophes pose a threat to human health, and the potential or substantial injury caused by ionizing radiation (IR) from medical treatment that cannot be ignored. Although the mechanisms of IR-induced damage to various organs have been gradually investigated, medical treatment of irradiated individuals is still based on clinical symptoms. Hence, minimally invasive biomarkers that can predict radiation damage are urgently needed for appropriate medical management after radiation exposure. In the field of radiation biomarker, finding molecular biomarkers to assess different levels of radiation damage is an important direction. In recent years, microRNAs have been widely reported as several diseases' biomarkers, such as cancer and cardiovascular diseases, and microRNAs are also of interest to the ionizing radiation field as radiation response molecules, thus researchers are turning attention to the potential of microRNAs as biomarkers in tumor radiation response and the radiation toxicity prediction of normal tissues. In this review, we summarize the distribution of microRNAs, the progress on research of microRNAs as markers of IR, and make a hypothesis about the origin and destination of microRNAs
Identifiants
pubmed: 35309926
doi: 10.3389/fcell.2022.861451
pii: 861451
pmc: PMC8927810
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
861451Informations de copyright
Copyright © 2022 Jia and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Cancer Prev Res (Phila). 2012 Mar;5(3):492-497
pubmed: 22158052
Radiat Res. 2017 Dec;188(6):626-635
pubmed: 28977780
Oncotarget. 2016 Sep 27;7(39):64233-64243
pubmed: 27572313
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):107-114
pubmed: 29051037
Biochim Biophys Acta Gene Regul Mech. 2017 Nov;1860(11):1127-1137
pubmed: 28851536
Sci Rep. 2017 Mar 17;7:44132
pubmed: 28303893
J Am Osteopath Assoc. 2014 Sep;114(9):702-11
pubmed: 25170040
Cell Signal. 2013 Jul;25(7):1625-34
pubmed: 23602933
Sci Transl Med. 2017 Mar 1;9(379):
pubmed: 28251902
PLoS One. 2013;8(2):e57603
pubmed: 23451251
J Cell Mol Med. 2020 Jul;24(14):7730-7742
pubmed: 32476275
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Clin Cancer Res. 2009 Sep 1;15(17):5473-7
pubmed: 19706812
Sci Rep. 2020 Mar 25;10(1):5424
pubmed: 32214144
Sci Transl Med. 2020 Jul 15;12(552):
pubmed: 32669422
Cell Death Dis. 2017 May 18;8(5):e2808
pubmed: 28518140
PLoS One. 2015 Aug 06;10(8):e0134827
pubmed: 26247844
Antioxid Redox Signal. 2014 Jul 10;21(2):293-312
pubmed: 24206455
Oncotarget. 2017 Mar 31;8(45):79201-79211
pubmed: 29108299
Sci Rep. 2018 Jan 22;8(1):1302
pubmed: 29358747
Clin Chem. 2010 Nov;56(11):1733-41
pubmed: 20847327
Sci Rep. 2021 Jul 21;11(1):14899
pubmed: 34290258
Mol Oncol. 2017 Dec;11(12):1673-1686
pubmed: 29024380
Int J Radiat Biol. 2011 Jul;87(7):653-62
pubmed: 21271940
Thorac Cancer. 2021 May;12(10):1549-1557
pubmed: 33759399
Urol Oncol. 2010 Nov-Dec;28(6):655-61
pubmed: 19375957
Br J Cancer. 2016 Jan 19;114(2):151-62
pubmed: 26671749
PLoS One. 2012;7(2):e31293
pubmed: 22347458
Expert Opin Biol Ther. 2009 Jun;9(6):703-711
pubmed: 19426115
Nucleic Acids Res. 2016 May 5;44(8):3865-77
pubmed: 26921406
Ann Diagn Pathol. 2020 Feb;44:151436
pubmed: 31865249
Int J Biol Sci. 2011 Mar 02;7(2):221-33
pubmed: 21448283
Biomed Res Int. 2014;2014:456323
pubmed: 25313363
Mol Med Rep. 2015 Sep;12(3):4683-4691
pubmed: 26082194
Cell Oncol (Dordr). 2020 Jun;43(3):505-511
pubmed: 32266559
RNA Biol. 2020 May;17(5):630-636
pubmed: 32009518
Expert Opin Drug Discov. 2015 May;10(5):497-517
pubmed: 25819367
Antioxid Redox Signal. 2021 Oct 10;35(11):849-862
pubmed: 32664737
Int J Mol Sci. 2020 Mar 20;21(6):
pubmed: 32245099
Nat Rev Clin Oncol. 2011 Jun 07;8(8):467-77
pubmed: 21647195
Expert Opin Drug Saf. 2019 Nov;18(11):1077-1090
pubmed: 31526195
Radiat Res. 2021 Nov 1;196(5):510-522
pubmed: 33857299
Biochem Biophys Res Commun. 2018 Jan 8;495(2):1648-1654
pubmed: 29223394
J Natl Cancer Inst. 2020 Mar 1;112(3):247-255
pubmed: 31161221
Front Genet. 2021 Jul 09;12:673926
pubmed: 34306018
Eur Urol Focus. 2018 Dec;4(6):825-833
pubmed: 28753866
Int J Mol Med. 2014 May;33(5):1243-9
pubmed: 24584717
Cell. 2012 Mar 16;148(6):1172-87
pubmed: 22424228
PLoS One. 2017 Mar 28;12(3):e0174771
pubmed: 28350824
Trends Cell Biol. 2012 Mar;22(3):125-32
pubmed: 22260888
Nat Rev Genet. 2010 Sep;11(9):597-610
pubmed: 20661255
Cancer Res. 2020 Oct 1;80(19):4266-4277
pubmed: 32816912
J Cancer Res Clin Oncol. 2020 Jan;146(1):105-115
pubmed: 31781865
J Cancer Res Clin Oncol. 2019 Jun;145(6):1635-1643
pubmed: 30923943
PLoS One. 2020 May 11;15(5):e0232411
pubmed: 32392259
Life Sci. 2021 Oct 1;282:119798
pubmed: 34237309
Radiother Oncol. 2014 Dec;113(3):379-84
pubmed: 25466375
Br J Cancer. 2015 Jun 30;113(1):76-82
pubmed: 26057452
Int J Oncol. 2015 Jan;46(1):17-27
pubmed: 25338714
Clin Chem. 2014 Jan;60(1):206-13
pubmed: 24212085
ACS Appl Bio Mater. 2021 Dec 20;4(12):8386-8395
pubmed: 35005951
Sci Rep. 2020 Mar 20;10(1):5161
pubmed: 32198434
Radiat Res. 2017 Sep;188(3):342-354
pubmed: 28632432
Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21105-10
pubmed: 22160723
Cell. 2007 Jun 29;129(7):1401-14
pubmed: 17604727
Cancer Med. 2020 Jul;9(14):5065-5074
pubmed: 32458566
Bioinformatics. 2017 May 15;33(10):1554-1560
pubmed: 28108447
Disaster Med Public Health Prep. 2011 Mar;5 Suppl 1:S32-44
pubmed: 21402810
Oncotarget. 2015 Jun 30;6(18):15995-6018
pubmed: 26201446
Int J Radiat Biol. 2019 Oct;95(10):1404-1413
pubmed: 30676169
Radiat Oncol. 2013 Dec 28;8:296
pubmed: 24373621
Am J Pathol. 2012 May;180(5):1787-97
pubmed: 22429968
PLoS One. 2016 Mar 23;11(3):e0152213
pubmed: 27006994
PLoS One. 2011;6(8):e22988
pubmed: 21857976
BMC Res Notes. 2014 Oct 10;7:715
pubmed: 25304816
Int J Radiat Biol. 2005 Mar;81(3):251-7
pubmed: 16019934
J Exp Clin Cancer Res. 2016 Jan 12;35:7
pubmed: 26754670
Curr Drug Metab. 2017 Oct 16;18(8):712-722
pubmed: 28524002
Sci Transl Med. 2015 May 13;7(287):287ra69
pubmed: 25972001
Mol Biotechnol. 2012 Jan;50(1):49-56
pubmed: 21567136
Curr Opin Cell Biol. 2009 Aug;21(4):575-81
pubmed: 19442504
Radiat Prot Dosimetry. 2019 Oct 1;184(3-4):482-485
pubmed: 31038713
Int J Radiat Oncol Biol Phys. 2021 Dec 1;111(5):1237-1249
pubmed: 34280472
Radiat Oncol. 2016 Apr 27;11:61
pubmed: 27117590
Dose Response. 2020 May 29;18(2):1559325820926735
pubmed: 32528236
Oncol Lett. 2020 Nov;20(5):236
pubmed: 32968458
Clin Chem. 2009 Apr;55(4):623-31
pubmed: 19246618
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Biomed Rep. 2021 Feb;14(2):24
pubmed: 33408858
Biochem Biophys Res Commun. 2020 Oct 20;531(3):328-334
pubmed: 32800335
Cell Death Dis. 2019 Mar 7;10(3):227
pubmed: 30846680
Radiat Environ Biophys. 2016 Nov;55(4):423-429
pubmed: 27561942
J Proteomics. 2010 Sep 10;73(10):1907-20
pubmed: 20601276
PLoS One. 2008;3(11):e3694
pubmed: 19002258
World J Hepatol. 2020 Nov 27;12(11):1031-1045
pubmed: 33312427
Mol Cell. 2010 Jul 9;39(1):133-44
pubmed: 20603081
PLoS One. 2016 Dec 1;11(12):e0167333
pubmed: 27907140
Int J Mol Sci. 2020 Mar 27;21(7):
pubmed: 32230970
Anticancer Res. 2020 Jun;40(6):3091-3096
pubmed: 32487603
Sci Rep. 2019 Feb 13;9(1):1949
pubmed: 30760738